In 2020 he was additionally appointed Professor at the Leiden University Medical Center (LUMC) in The Netherlands (oration on with the title “A cycle of life of T cell activation”). Dr Blank is committed to teaching, lecturing on medical courses at the NKI-AVL and the Medical School of the University of Regensburg, where he was appointed Professor in 2015. In addition to his academic background, Dr Blank obtained his Master of Business Administration (MBA), from the University of Warwick, England, UK (2006). In 2010, Dr Blank became University Lecturer (Privatdozent) at the University of Regensburg.
Since 2007, he has been appointed Staff Member at the Department of Medical Oncology, and a Group Leader at the Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NKI-AVL), Amsterdam. Dr Blank has obtained two Specialist Degrees in Internal Medicine (2007) and in Hematology/Oncology (2009). Subsequently he was appointed as Physician and Research Group Leader at the Department of Hematology and Oncology, University of Regensburg, Germany (2003–2007). During 2001–2003, Dr Blank held a Postdoctoral Research Fellowship at the lab of Professor Thomas Gajewski, University of Chicago, IL, USA. He went on to attain the position of Physician at the Department of Hematology and Oncology, University of Regensburg, Germany (1998–2001). He worked as Junior House Officer (1997–1998) at the University Clinic Munich, at the Royal Infirmary of Edinburgh, and the University of Birmingham. Academic careerĬhristian Blank obtained his MD from the Medical School of the Technical University Munich, Germany, where he also completed his Doctoral thesis (summa cum laude) at the Department for Medical Microbiology and in 1997. Our current research focus is on personalizing the intensity of therapy, extent of surgery and frequency of the follow-up. Our group has pioneered neoadjuvant checkpoint inhibition in melanoma, achieving unparalleled high response rates in early-stage disease. A major advantage of this therapy is the longevity of response, if it occurs. Cancer ImmunotherapyĬancer Immunotherapy is a novel therapeutic option with the aim to learn the body’s own immune system to attack and eliminate cancers.Ī subgroup of cancer immunotherapy is the modulation of checkpoints, negative of positive signaling molecules on immune cells. In addition, he is professor at the University of Regensburg/Germany, and is he founding and faculty member of the International Neoadjuvant Melanoma Consortium (INMC). Blank is professor for Internal Medicine, especially clinical research on cancer immunotherapy (LUMC) and staff member at the Netherlands Cancer Institute (NKI). Perhaps the most tangible evidence of the University’s abiding interest in research is the presence of our many research facilities on campus.Christian U. You will find that Catholic University’s commitment to research is demonstrated in a variety of ways - engaging both undergraduates and graduate students in research projects, frequent faculty and student research presentations at national and international academic events, and numerous published articles and books by our faculty.
0 kommentar(er)
